27 Oct '23
PRINCETON, N.J. , Oct. 27, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2023 operating and financial results after the...
05 Oct '23
PRINCETON, N.J. , Oct. 05, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan , Chief Executive Officer, will present at...
14 Aug '23
Readout of topline results expected before year-end on FDA Breakthrough Device, DrugSorb-ATR.  Sets stage for potential regulatory submission to FDA and Health Canada as the first reversal agent for the blood thinner, Brilinta ® PRINCETON, N.J. , Aug....
01 Aug '23
Q2 2023 Total Revenue was $9.4 million , an 11% increase from $8.5 million in Q2 2022. Product sales rose 10% to $8.1 million vs $7.3 million in Q2 2022. Product gross margins grew 700 basis points to 74% PRINCETON, N.J. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a...
Displaying 1 - 10 of 30